Co-reporter:Rachel Pricer, Jason E Gestwicki, and Anna K Mapp
Accounts of Chemical Research March 21, 2017 Volume 50(Issue 3) pp:584-584
Publication Date(Web):March 21, 2017
DOI:10.1021/acs.accounts.6b00565
Conformationally heterogenous or “fuzzy” proteins have often been described as lacking specificity in binding and in function. The activation domains, for example, of transcriptional activators were labeled as negative noodles, with little structure or specificity. However, emerging data illustrates that the opposite is true: conformational heterogeneity enables context-specific function to emerge in response to changing cellular conditions and, furthermore, allows a single structural motif to be used in multiple settings. A further benefit is that conformational heterogeneity can be harnessed for the discovery of allosteric drug-like modulators, targeting critical pathways in protein homeostasis and transcription.
Co-reporter:Amanda Dugan, Chinmay Y. Majmudar, Rachel Pricer, Sherry Niessen, Jody K. Lancia, Hugo Yik-Hong Fung, Benjamin F. Cravatt, and Anna K. Mapp
Journal of the American Chemical Society 2016 Volume 138(Issue 38) pp:12629-12635
Publication Date(Web):September 9, 2016
DOI:10.1021/jacs.6b07680
The network of activator protein-protein interactions (PPIs) that underpin transcription initiation is poorly defined, particularly in the cellular context. The transient nature of these contacts and the often low abundance of the participants present significant experimental hurdles. Through the coupling of in vivo covalent chemical capture and shotgun LC-MS/MS (MuDPIT) analysis, we can trap the PPIs of transcriptional activators in a cellular setting and identify the binding partners in an unbiased fashion. Using this approach, we discover that the prototypical activators Gal4 and VP16 target the Snf1 (AMPK) kinase complex via direct interactions with both the core enzymatic subunit Snf1 and the exchangeable subunit Gal83. Further, we use a tandem reversible formaldehyde and irreversible covalent chemical capture approach (TRIC) to capture the Gal4-Snf1 interaction at the Gal1 promoter in live yeast. Together, these data support a critical role for activator PPIs in both the recruitment and positioning of important enzymatic complexes at a gene promoter and represent a technical advancement in the discovery of new cellular binding targets of transcriptional activators.
Co-reporter:Jean M. Lodge, T. Justin Rettenmaier, James A. Wells, William C. Pomerantz and Anna K. Mapp
MedChemComm 2014 vol. 5(Issue 3) pp:370-375
Publication Date(Web):09 Jan 2014
DOI:10.1039/C3MD00356F
Tethering is a screening technique for discovering small-molecule fragments that bind to pre-determined sites via formation of a disulphide bond. Tethering screens traditionally rely upon mass spectrometry to detect disulphide bond formation, which requires a time-consuming liquid chromatography step. Here we show that tethering can be performed rapidly and inexpensively using a homogenous fluorescence polarization (FP) assay that detects displacement of a peptide ligand from the protein target as an indirect readout of disulphide formation. We apply this method, termed FP tethering, to identify fragments that disrupt the protein–protein interaction between the KIX domain of the transcriptional coactivator CBP and the transcriptional activator peptide pKID.
Co-reporter:Ningkun Wang;Jean M. Lodge;Carol A. Fierke
PNAS 2014 Volume 111 (Issue 33 ) pp:12061-12066
Publication Date(Web):2014-08-19
DOI:10.1073/pnas.1406033111
Allosteric binding events play a critical role in the formation and stability of transcriptional activator–coactivator complexes,
perhaps in part due to the often intrinsically disordered nature of one or more of the constituent partners. The kinase-inducible
domain interacting (KIX) domain of the master coactivator CREB binding protein/p300 is a conformationally dynamic domain that
complexes with transcriptional activators at two discrete binding sites in allosteric communication. The complexation of KIX
with the transcriptional activation domain of mixed-lineage leukemia protein leads to an enhancement of binding by the activation
domain of CREB (phosphorylated kinase-inducible domain of CREB) to the second site. A transient kinetic analysis of the ternary
complex formation aided by small molecule ligands that induce positive or negative cooperative binding reveals that positive
cooperativity is largely governed by stabilization of the bound complex as indicated by a decrease in koff. Thus, this suggests the increased binding affinity for the second ligand is not due to an allosteric creation of a more
favorable binding interface by the first ligand. This is consistent with data from us and from others indicating that the
on rates of conformationally dynamic proteins approach the limits of diffusion. In contrast, negative cooperativity is manifested
by alterations in both kon and koff, suggesting stabilization of the binary complex.
Co-reporter:Jody K. Lancia;Adaora Nwokoye;Ama Dugan;Cassra Joiner;Rachel Pricer
Biopolymers 2014 Volume 101( Issue 4) pp:391-397
Publication Date(Web):
DOI:10.1002/bip.22395
ABSTRACT
Protein–protein interactions (PPIs) are essential for implementing cellular processes and thus methods for the discovery and study of PPIs are highly desirable. An emerging method for capturing PPIs in their native cellular environment is in vivo covalent chemical capture, a method that uses nonsense suppression to site specifically incorporate photoactivable unnatural amino acids (UAAs) in living cells. However, in one study we found that this method did not capture a PPI for which there was abundant functional evidence, a complex formed between the transcriptional activator Gal4 and its repressor protein Gal80. Here we describe the factors that influence the success of covalent chemical capture and show that the innate reactivity of the two UAAs utilized, (p-benzoylphenylalanine (pBpa) and p-azidophenylalanine (pAzpa)), plays a profound role in the capture of Gal80 by Gal4. Based upon these data, guidelines are outlined for the successful use of in vivo photo-crosslinking to capture novel PPIs and to characterize the interfaces. © 2013 Wiley Periodicals, Inc. Biopolymers 101: 391–397, 2014.
Co-reporter:Ningkun Wang ; Chinmay Y. Majmudar ; William C. Pomerantz ; Jessica K. Gagnon ; Jack D. Sadowsky ; Jennifer L. Meagher ; Taylor K. Johnson ; Jeanne A. Stuckey ; Charles L. Brooks ; III; James A. Wells
Journal of the American Chemical Society 2013 Volume 135(Issue 9) pp:3363-3366
Publication Date(Web):February 5, 2013
DOI:10.1021/ja3122334
Like many coactivators, the GACKIX domain of the master coactivator CBP/p300 recognizes transcriptional activators of diverse sequence composition via dynamic binding surfaces. The conformational dynamics of GACKIX that underlie its function also render it especially challenging for structural characterization. We have found that the ligand discovery strategy of Tethering is an effective method for identifying small-molecule fragments that stabilize the GACKIX domain, enabling for the first time the crystallographic characterization of this important motif. The 2.0 Å resolution structure of GACKIX complexed to a small molecule was further analyzed by molecular dynamics simulations, which revealed the importance of specific side-chain motions that remodel the activator binding site in order to accommodate binding partners of distinct sequence and size. More broadly, these results suggest that Tethering can be a powerful strategy for identifying small-molecule stabilizers of conformationally malleable proteins, thus facilitating their structural characterization and accelerating the discovery of small-molecule modulators.
Co-reporter:Andrea D. Thompson, Amanda Dugan, Jason E. Gestwicki, and Anna K. Mapp
ACS Chemical Biology 2012 Volume 7(Issue 8) pp:1311
Publication Date(Web):June 24, 2012
DOI:10.1021/cb300255p
Multiprotein complexes such as the transcriptional machinery, signaling hubs, and protein folding machines are typically composed of at least one enzyme combined with multiple non-enzymes. Often the components of these complexes are incorporated in a combinatorial manner, in which the ultimate composition of the system helps dictate the type, location, or duration of cellular activities. Although drugs and chemical probes have traditionally targeted the enzyme components, emerging strategies call for controlling the function of protein complexes by modulation of protein–protein interactions (PPIs). However, the challenges of targeting PPIs have been well documented, and the diversity of PPIs makes a “one-size-fits-all” solution highly unlikely. These hurdles are particularly daunting for PPIs that encompass large buried surface areas and those with weak affinities. In this Review, we discuss lessons from natural systems, in which allostery and other mechanisms are used to overcome the challenge of regulating the most difficult PPIs. These systems may provide a blueprint for identifying small molecules that target challenging PPIs and affecting molecular decision-making within multiprotein systems.
Co-reporter:William C. Pomerantz, Ningkun Wang, Ashley K. Lipinski, Rurun Wang, Tomasz Cierpicki, and Anna K. Mapp
ACS Chemical Biology 2012 Volume 7(Issue 8) pp:1345
Publication Date(Web):June 24, 2012
DOI:10.1021/cb3002733
The conformationally dynamic binding surfaces of transcription complexes present a particular challenge for ligand discovery and characterization. In the case of the KIX domain of the master coactivator CBP/p300, few small molecules have been reported that target its two allosterically regulated binding sites despite the important roles that KIX plays in processes ranging from memory formation to hematopoiesis. Taking advantage of the enrichment of aromatic amino acids at protein interfaces, here we show that the incorporation of six 19F-labeled aromatic side chains within the KIX domain enables recapitulation of the differential binding footprints of three natural activator peptides (MLL, c-Myb, and pKID) in complex with KIX and effectively reports on allosteric changes upon binding using 1D NMR spectroscopy. Additionally, the examination of both the previously described KIX protein–protein interaction inhibitor Napthol-ASE-phosphate and newly discovered ligand 1-10 rapidly revealed both the binding sites and the affinities of these small molecules. Significantly, the utility of using fluorinated transcription factors for ligand discovery was demonstrated through a fragment screen leading to a new low molecular weight fragment ligand for CBP/p300, 1G7. Aromatic amino acids are enriched at protein–biomolecule interfaces; therefore, this quantitative and facile approach will be broadly useful for studying dynamic transcription complexes and screening campaigns complementing existing biophysical methods for studying these dynamic interfaces.
Co-reporter:Christopher E. Taylor, Quintin Pan, and Anna K. Mapp
ACS Medicinal Chemistry Letters 2012 Volume 3(Issue 1) pp:30
Publication Date(Web):November 14, 2011
DOI:10.1021/ml200186r
In spite of their considerable therapeutic potential, the development of highly potent and selective transcriptional inhibitors has proven elusive. We demonstrate that combinations of transcriptional inhibitors of erbB2 expression and existing therapeutic agents that target erbB2 activity and lifetime lead to a synergistic increase in activity, with dose reductions as high as 30-fold as compared to individual agents. The synergy is selective for erbB2 overexpressing cancer cells. These results highlight the potential of a generalizable approach that will improve the utility of transcriptional inhibitors as both biochemical tools and potential therapeutics.Keywords: Antitumor agents; gene expression; protein−protein interactions; synergy; transcription
Co-reporter:Dr. Chinmay Y. Majmudar;Dr. Jonas W. Højfeldt;Carl J. Arevang;Dr. William C. Pomerantz;Jessica K. Gagnon;Pamela J. Schultz;Laura C. Cesa;Conor H. Doss;Dr. Steven P. Rowe;Victor Vásquez;Dr. Giselle Tamayo-Castillo;Dr. Tomasz Cierpicki;Dr. Charles L. Brooks III;Dr. David H. Sherman;Dr. Anna K. Mapp
Angewandte Chemie 2012 Volume 124( Issue 45) pp:11420-11424
Publication Date(Web):
DOI:10.1002/ange.201206815
Co-reporter:Dr. Chinmay Y. Majmudar;Dr. Jonas W. Højfeldt;Carl J. Arevang;Dr. William C. Pomerantz;Jessica K. Gagnon;Pamela J. Schultz;Laura C. Cesa;Conor H. Doss;Dr. Steven P. Rowe;Victor Vásquez;Dr. Giselle Tamayo-Castillo;Dr. Tomasz Cierpicki;Dr. Charles L. Brooks III;Dr. David H. Sherman;Dr. Anna K. Mapp
Angewandte Chemie International Edition 2012 Volume 51( Issue 45) pp:11258-11262
Publication Date(Web):
DOI:10.1002/anie.201206815
Co-reporter:Jonas W. Højfeldt, Aaron R. Van Dyke and Anna K. Mapp
Chemical Society Reviews 2011 vol. 40(Issue 8) pp:4286-4294
Publication Date(Web):23 Jun 2011
DOI:10.1039/C1CS15050B
The human body is comprised of several hundred distinct cell types that all share a common genomic template. This diversity arises from regulated expression of individual genes. The first critical step in this process is transcription and is governed by a large number of transcription factors. Small molecules that can alter transcription hold tremendous utility as chemical probes and therapeutics. To fully realize their potential, however, artificial transcription factors must be able to orchestrate protein recruitment at gene promoters just like their natural counterparts. This tutorial review surveys the discovery of small ligands (drug-like molecules and short peptides) that bind transcriptional coregulatory proteins, and thus comprise one of the two essential characteristics of a transcription factor. By joining these ligands to DNA-targeting moieties, one can construct a bifunctional molecule that recruits its protein target to specific genes and controls gene transcription.
Co-reporter:Malathy Krishnamurthy, Amanda Dugan, Adaora Nwokoye, Yik-Hong Fung, Jody K. Lancia, Chinmay Y. Majmudar, and Anna K Mapp
ACS Chemical Biology 2011 Volume 6(Issue 12) pp:1321
Publication Date(Web):October 6, 2011
DOI:10.1021/cb200308e
Currently there are few methods suitable for the discovery and characterization of transient, moderate affinity protein–protein interactions in their native environment, despite their prominent role in a host of cellular functions including protein folding, signal transduction, and transcriptional activation. Here we demonstrate that a genetically encoded photoactivatable amino acid, p-benzoyl-l-phenylalanine, can be used to capture transient and/or low affinity binding partners in an in vivo setting. In this study, we focused on ensnaring the coactivator binding partners of the transcriptional activator VP16 in S. cerevisiae. The interactions between transcriptional activators and coactivators in eukaryotes are moderate in affinity and short-lived, and due in part to these characteristics, identification of the direct binding partners of activators in vivo has met with only limited success. We find through in vivo photo-cross-linking that VP16 contacts the Swi/Snf chromatin-remodeling complex through the ATPase Snf2(BRG1/BRM) and the subunit Snf5 with two distinct regions of the activation domain. An analogous experiment with Gal4 reveals that Snf2 is also a target of this activator. These results suggest that Snf2 may be a valuable target for small molecule probe discovery given the prominent role the Swi/Snf complex family plays in development and in disease. More significantly, the successful implementation of the in vivo cross-linking methodology in this setting demonstrates that it can be applied to the discovery and characterization of a broad range of transient and/or modest affinity protein–protein interactions.
Co-reporter:Caleb A. Bates;William C. Pomerantz
Biopolymers 2011 Volume 95( Issue 1) pp:17-23
Publication Date(Web):
DOI:10.1002/bip.21548
Abstract
Previously it was demonstrated that amphipathic isoxazolidines are able to functionally replace the transcriptional activation domains of endogenous transcriptional activators. In addition, in vitro binding studies suggested that a key binding partner of these molecules is the CREB Binding Protein (CBP), more specifically the KIX domain within this protein. Here we show that CBP plays an essential role in the ability of isoxazolidine transcriptional activation domains to activate transcription in cells. Consistent with this model, isoxazolidines are able to function as competitive inhibitors of the activators MLL and Jun, both of which utilize a binding interaction with KIX to up-regulate transcription. Further, modification of the N2 side chain produced three analogs with enhanced potency against Jun-mediated transcription, although increased cytotoxicity was also observed. Collectively these small KIX-binding molecules will be useful tools for dissecting the role of the KIX domain in a variety of pathological processes. © 2010 Wiley Periodicals, Inc. Biopolymers 95: 17–23, 2011.
Co-reporter:Chinmay Y. Majmudar ; Lori W. Lee ; Jody K. Lancia ; Adaora Nwokoye ; Qian Wang ; Amberlyn M. Wands ; Lei Wang
Journal of the American Chemical Society 2009 Volume 131(Issue 40) pp:14240-14242
Publication Date(Web):September 18, 2009
DOI:10.1021/ja904378z
Protein−protein interactions play an essential role in cellular function, and methods to discover and characterize them in their native context are of paramount importance for gaining a deeper understanding of biological networks. In this study, an enhanced nonsense suppression system was utilized to incorporate the nonnatural amino acid p-benzoyl-l-phenylalanine (pBpa) throughout the transcriptional activation domain of the prototypical eukaryotic transcriptional activator Gal4 in vivo (S. cerevisiae). Functional studies of the pBpa-containing Gal4 mutants suggest that this essential binding interface of Gal4 is minimally impacted by these substitutions, with both transcriptional activity and sensitivity to growth conditions maintained. Further supporting this are in vivo cross-linking studies, including the detection of a key binding partner of Gal4, the inhibitor protein Gal80. Cross-linking with a range of pBpa-containing mutants revealed a Gal4•Gal80 binding interface that extends beyond that previously predicted by conventional strategies. Thus, this approach can be broadened to the discovery of novel binding partners of transcription factors, information that will be critical for the development of therapeutically useful small molecule modulators of these protein−protein interactions.
Co-reporter:Sara J. Buhrlage, Caleb A. Bates, Steven P. Rowe, Aaron R. Minter, Brian B. Brennan, Chinmay Y. Majmudar, David E. Wemmer, Hashim Al-Hashimi and Anna K. Mapp
ACS Chemical Biology 2009 Volume 4(Issue 5) pp:335
Publication Date(Web):April 6, 2009
DOI:10.1021/cb900028j
Small molecules that reconstitute the binding mode(s) of a protein and in doing so elicit a programmed functional response offer considerable advantages in the control of complex biological processes. The development challenges of such molecules are significant, however. Many protein–protein interactions require multiple points of contact over relatively large surface areas. More significantly, several binding modes can be superimposed upon a single sequence within a protein, and a true small molecule replacement must be preprogrammed for such multimodal binding. This is the case for the transcriptional activation domain or TAD of transcriptional activators as these motifs utilize a poorly characterized multipartner binding profile in order to stimulate gene expression. Here we describe a unique class of small molecules that exhibit both function and a binding profile analogous to natural transcriptional activation domains. Of particular note, the small molecules are the first reported to bind to the KIX domain within the CREB binding protein (CBP) at a site that is utilized by natural activators. Further, a comparison of functional and nonfunctional small molecules indicates that an interaction with CBP is a key contributor to transcriptional activity. Taken together, the evidence suggests that the small molecule TADs mimic both the function and mechanism of their natural counterparts and thus present a framework for the broader development of small molecule transcriptional switches.
Co-reporter:Ryan J. Casey, Jean-Paul Desaulniers, Jonas W. Hojfeldt, Anna K. Mapp
Bioorganic & Medicinal Chemistry 2009 Volume 17(Issue 3) pp:1034-1043
Publication Date(Web):1 February 2009
DOI:10.1016/j.bmc.2008.02.045
Molecules that can reconstitute the function of transcriptional activators hold enormous potential as therapeutic agents and as mechanistic probes. Previously we described an isoxazolidine bearing functional groups similar to natural transcriptional activators that up-regulates transcription 80-fold at 1 μM in cell culture. In this study, we analyze analogs of this molecule to define key characteristics of small molecules that function as transcriptional activation domains in cells. Conformational rigidity is an important contributor to function as is an overall amphipathic substitution pattern. Using these criteria, we identified additional molecular scaffolds with excellent (∼60-fold) activity as transcriptional activation domains. These results point the way for the creation of new generations of small molecules with this function.
Co-reporter:Lori W. Lee, Christopher E.C. Taylor, Jean-Paul Desaulniers, Manchao Zhang, Jonas W. Højfeldt, Quintin Pan, Anna K. Mapp
Bioorganic & Medicinal Chemistry Letters 2009 Volume 19(Issue 21) pp:6233-6236
Publication Date(Web):1 November 2009
DOI:10.1016/j.bmcl.2009.08.090
Small molecules that mimic the transcriptional activation domain of eukaryotic transcriptional activators have the potential to serve as effective inhibitors of transcriptional processes. Here we show that one class of transcriptional activation domain mimics, amphipathic isoxazolidines, can be converted into inhibitors of gene expression mediated by the transcriptional activator ESX through small structural modifications. Addition of the small molecules leads to decreased expression of the cell surface growth receptor ErbB2(Her2) in ErbB2-positive cancer cells and, correspondingly, decreased proliferation.
Co-reporter:Chinmay Y. Majmudar, Anne E. Labut, Anna K. Mapp
Bioorganic & Medicinal Chemistry Letters 2009 Volume 19(Issue 14) pp:3733-3735
Publication Date(Web):15 July 2009
DOI:10.1016/j.bmcl.2009.05.045
There is tremendous interest in developing activator artificial transcription factors that functionally mimic endogenous transcriptional activators for use as mechanistic probes, as components of synthetic cell circuitry, and in transcription-targeted therapies. Here, we demonstrate that a phage display selection against the transcriptional activation domain binding motif of the coactivator Tra1(TRRAP) produces distinct sequences that function with similar binding modes and potency as natural activators. These findings set the stage for binding screens with small molecule libraries against TAD binding motifs to yield next-generation small molecule TADs.
Co-reporter:ChinmayY. Majmudar Dr.;Bo Wang;JeniferK. Lum Dr.;Kristina Håkansson Dr. ;AnnaK. Mapp Dr.
Angewandte Chemie International Edition 2009 Volume 48( Issue 38) pp:7021-7024
Publication Date(Web):
DOI:10.1002/anie.200902669
Co-reporter:ChinmayY. Majmudar Dr.;Bo Wang;JeniferK. Lum Dr.;Kristina Håkansson Dr. ;AnnaK. Mapp Dr.
Angewandte Chemie 2009 Volume 121( Issue 38) pp:7155-7158
Publication Date(Web):
DOI:10.1002/ange.200902669
Co-reporter:Sara J. Buhrlage, Bin Chen, Anna K. Mapp
Tetrahedron 2009 65(16) pp: 3305-3313
Publication Date(Web):
DOI:10.1016/j.tet.2008.12.062
Co-reporter:Steven P. Rowe
Biopolymers 2008 Volume 89( Issue 7) pp:578-581
Publication Date(Web):
DOI:10.1002/bip.20946
Abstract
Both genetic and biochemical data suggest that transcriptional activators with little sequence homology nevertheless function through interaction with a shared group of coactivators. Here we show that a series of peptidomimetic transcriptional activation domains interact under cell-fiee and cellular conditions with the metazoan coactivator CBP despite differences in the positioning and identity of the constituent functional groups. Taken together, these results suggest that a key activator binding site within CBP is permissive, accepting multiple arrangements of hydrophobic functional groups. Further, this permissiveness is also observed with a coactivator from S. cerevisiae. Thus, the design of small molecule mimics of transcriptional activation domains with broad function may be more straightforward than previously envisioned. © 2008 Wiley Periodicals, Inc. Biopolymers 89: 578–581, 2008.
This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com
Co-reporter:Anna K. Mapp and Aseem Z. Ansari
ACS Chemical Biology 2007 Volume 2(Issue 1) pp:62
Publication Date(Web):January 19, 2007
DOI:10.1021/cb600463w
Designer molecules that can be used to impose exogenous control on gene transcription, artificial transcription factors (ATFs), are highly desirable as mechanistic probes of gene regulation, as potential therapeutic agents, and as components of cell-based devices. Recently, several advances have been made in the design of ATFs that activate gene transcription (activator ATFs), including reports of small-molecule-based systems and ATFs that exhibit potent activity. However, the many open mechanistic questions about transcriptional activators, in particular, the structure and function of the transcriptional activation domain (TAD), have hindered rapid development of synthetic ATFs. A compelling need thus exists for chemical tools and insights toward a more detailed portrait of the dynamic process of gene activation. Keywords: Activator ATF: An activator ATF up-regulates specific genes or sets of genes by binding to a particular sequence of DNA and interacting with one or more components of the transcriptional machinery. Molecules that indirectly affect gene activation, for example, by stimulating signal transduction cascades or altering DNA structure, are thus not activator ATFs.; Artificial transcription factor (ATF): An ATF is a designer molecule that seeks out specific genes or groups of genes and directly regulates them either positively or negatively. An ATF typically contains at least two functional domains, a DNA binding domain and a regulatory domain.; Coactivator: A protein that interacts with the transcriptional activation domain of a DNA-bound transcriptional activator and participates in the gene-activation process.; DNA binding domain (DBD): One of the two key domains of an activator ATF, the DBD provides the gene-targeting specificity of the molecule.; Transcriptional activation domain (TAD): One of the two key domains of an activator ATF, the TAD dictates the timing and extent of transcriptional up-regulation through binding interactions with one or more components of the transcriptional machinery.; Transcriptional activator: These natural transcription factors are key players in the cascade of events that lead to gene activation. Minimally composed of a DNA binding domain and a transcriptional activation domain, activators function in a signal-responsive fashion to regulate the timing and extent of gene-specific activation.
Co-reporter:Jenifer K. Lum Dr.
ChemBioChem 2005 Volume 6(Issue 8) pp:
Publication Date(Web):23 JUN 2005
DOI:10.1002/cbic.200500036
Artificial transcriptional activators show great promise as tools to probe activator function as well as provide a basis for future transcription-based therapeutics. This review highlights the current methods used to isolate artificial activation domains as well as novel peptidic and small-molecule activation domains recently identified. Considerations and challenges in artificial activator design will also be discussed.
Co-reporter:Jonas W. Højfeldt, Aaron R. Van Dyke and Anna K. Mapp
Chemical Society Reviews 2011 - vol. 40(Issue 8) pp:NaN4294-4294
Publication Date(Web):2011/06/23
DOI:10.1039/C1CS15050B
The human body is comprised of several hundred distinct cell types that all share a common genomic template. This diversity arises from regulated expression of individual genes. The first critical step in this process is transcription and is governed by a large number of transcription factors. Small molecules that can alter transcription hold tremendous utility as chemical probes and therapeutics. To fully realize their potential, however, artificial transcription factors must be able to orchestrate protein recruitment at gene promoters just like their natural counterparts. This tutorial review surveys the discovery of small ligands (drug-like molecules and short peptides) that bind transcriptional coregulatory proteins, and thus comprise one of the two essential characteristics of a transcription factor. By joining these ligands to DNA-targeting moieties, one can construct a bifunctional molecule that recruits its protein target to specific genes and controls gene transcription.